BALAXI Overseas Private LIMITED�has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
BALAXI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
BALAXI Pharmaceuticals has informed the exchanges that its promoter-group entity, BALAXI Overseas Private Limited, has submitted a disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation requires non-individual acquirers (such as corporate bodies within a promoter group) to disclose details of their shareholding and any encumbrances on shares held in the listed company. The filing itself does not state whether this is a fresh acquisition, sale, pledge creation, or release. The full contents of the disclosure (with shareholding numbers and any changes) are not visible in this announcement and would be in the attached document submitted to the exchange.
Since the specific nature of the disclosure (buy/sell/pledge) and any change in numbers are not visible in this announcement, there is no immediate clear price impact. Investors should watch for any follow-up filings or the actual Regulation 31(4) document for details on whether promoter-group holdings have changed or any new encumbrance has been created on the company's shares.